Rifadin Iv Generic Name & Formulations
Legal Class
General Description
Pharmacological Class
See Also
How Supplied
Manufacturer
Mechanism of Action
Rifadin Iv Indications
Indications
Rifadin Iv Dosage and Administration
Adult
Children
Rifadin Iv Contraindications
Contraindications
Rifadin Iv Boxed Warnings
Not Applicable
Rifadin Iv Warnings/Precautions
Warnings/Precautions
Meningococcal: reserve rifampin for cases where high risk of meningococcal disease exists; confirm diagnosis. Not recommended for intermittent therapy (risk of rare renal hypersensitivity reactions). Monitor for hypersensitivity or severe cutaneous reactions (eg, SJS, TEN, DRESS); discontinue if occur. Monitor for signs of liver injury (esp. in prolonged treatment). If hepatic impaired: obtain LFTs at baseline, then every 2–4 weeks during therapy. Discontinue if signs of hepatic damage occur or worsen. Vitamin K-dependent coagulation disorders, bleeding; monitor. Pulmonary toxicity. Thrombotic microangiopathy (including thrombotic thrombocytopenic purpura, hemolytic uremia syndrome). Diabetes. May stain teeth, body secretions, contact lenses. IV: avoid extravasation. Elderly. Pregnancy. Nursing mothers: not recommended.
Rifadin Iv Pharmacokinetics
Elimination
Rifadin Iv Interactions
Interactions
Rifadin Iv Adverse Reactions
Adverse Reactions
GI disturbances, jaundice, headache, fever, drowsiness, fatigue, ataxia, dizziness, inability to concentrate, mental confusion, muscular weakness, pain in extremities, generalized numbness, visual disturbances, elevated BUN and serum uric acid, menstrual disturbances, urticaria, rash, edema; hepatotoxicity, hepatitis, abnormal LFTs, cholestasis, paradoxical drug reaction, interstitial lung disease; rare: blood dyscrasias, anaphylaxis.
Rifadin Iv Clinical Trials
See Literature
Rifadin Iv Note
Not Applicable
Rifadin Iv Patient Counseling
See Literature